George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
To meet institutional demand and improve liquidity. Really or just taking advantage of the current share price for directors to sell their shares from the Group's Growth Share Scheme. Call me sceptical but are their sales really going to improve liquidity in a share that does not attract much institutional interest. I cannot complain though as I sold at 82p for a reasonable profit and await the pull back to buy again.
Agreed no special dividend. Share price will fall to reflect cash taken out of the business and subsequent effect upon the balance sheet. Much better to invest it wisely in the remaining Aviva business assuming this to be eps enhancing. Selling, AB, is probably the easy part, investing wisely for a return will be your real test.
Market down, Aviva up and by a good margin maintained through to the close. Surely recent broker upgrades and price targets at circa 440 are not responsible for the increase. However brokers analysts probably have access to Aviva’s management whereby price target upgrades will help AB in her quest to increase shareholder value. Looking forward to results, details of sales and a share price moving towards 400p.
You are certainly not alone. My first purchase over a year ago now was at 420p, a point at which the share price started to slide before the bear market. I did buy at 360p and 315p but not in sufficient quantity to give me an overall profit. I do believe that we will see £4 in the next six months assuming no market downturn at which time I will sell. I hold on because experience has taught me that it is often foolish to sell a share merely because of a paper loss. There are exceptions of course but I do not believe Aviva to be one of those. Good luck to all and let’s hope that Amanda Blanc can indeed increase shareholder value as she has publicly stated.
As is the case for MISSION, forecasts for peers remain highly subjective to assumptions on the speed and scale of the recovery, so we have continued to look at an average over FY19, FY20e and FY21e. MISSION’s shares trade at a discount to peers on EV/EBIT (11.5x 2021) and P/E on this basis. Parity indicates a share price of 87.6p (up from 76.9p in December), reflecting positive share price performances in the sector as advertising spending levels look set to recover. This is 33% above the current level.
It looks to me and I could be completely wrong, that there is some demand for these shares, which can only be satisfied through increasing the bid to attract sellers. I have no intention of selling mine until we are back to 100p. Any other views for the comparative strength lately?
Whilst only a small number of trades today some are quite large. Bid showing at 58p but I was offered 61p so obviously there is buyer demand here. Any pull back and I shall be adding looking for a longer term return to pre Covid valuation.
Written by a child maybe but the market likes it on a down day for the FTSE. Now hopefully we will see a steady share price rise over the coming months as we learn of the new CEO’s plans. She deserves to be given a chance to, as she says enhance shareholder value as a priority.
Let’s hope that Aviva do not disappoint the market tomorrow. Definitely looks like those in the know anticipate a share price rise tomorrow. My holding would certainly benefit from any uplift in the share price.
Agreed but fed up of seeing LGEN and PRU rising at a bigger percentage most days. I am a long term investor here having bought at prices between 260 and 420p. In the past market meltdowns Aviva dividends have always compensated for loss of capital. Let’s hope that the BOD who have not taken a pay cut during this pandemic reinstate the dividend soon.